BamSEC and AlphaSense Join Forces
Learn More

Ligand Pharmaceuticals Incorporated – Material Contracts

NASDAQ: LGND    
Share price (3/27/26): $195.48    
Market cap (3/27/26): $3.898 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 30 pages The Securities Represented Hereby (The “Warrants”) Were Originally Issued in a Transaction Exempt From Registration Under the United States Securities Act of 1933, as Amended (The “Securities Act”), and the Warrants May Not Be Offered, Sold or Otherwise Transferred Except Pursuant to a Registration Statement Under the Securities Act or an Applicable Exemption From the Registration Requirements Thereof. [Dealer Name] [Dealer Address] August [__], 2025 To: Ligand Pharmaceuticals Incorporated 555 Heritage Drive, Suite 200 Jupiter, Fl 33458 Re: [Base]1[additional]2 Warrants
12/34/56
EX-10.1
from 8-K 31 pages [Dealer Name] [Dealer Address] August [ _], 2025 To: Ligand Pharmaceuticals Incorporated 555 Heritage Drive, Suite 200 Jupiter Fl, 33458 Re: [Base]1[additional]2 Call Option Transaction
12/34/56
EX-10.2
from 10-Q 8 pages Severance Agreement and General Release
12/34/56
EX-10.2
from 10-Q 88 pages Purchase and Sale Agreement Dated as of May 6, 2024 by and Among Agenus Inc., Agenus Royalty Fund, LLC, Agenus Holdings 2024, LLC and Ligand Pharmaceuticals Incorporated
12/34/56
EX-10.2
from S-8 2 pages Amendment to the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan
12/34/56
EX-10.45
from 10-K 17 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Ligand Pharmaceuticals Incorporated Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Ligand Pharmaceuticals Incorporated if Publicly Disclosed
12/34/56
EX-10.44
from 10-K 3 pages First Amendment to Development Funding and Royalties Agreement
12/34/56
EX-10.12
from 10-K 1 page Amendment to Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan
12/34/56
EX-10.1
from 10-Q 3 pages Ligand Pharmaceuticals Incorporated Director Compensation and Stock Ownership Policy (Amended and Restated Effective August 4, 2023) I. Director Compensation
12/34/56
EX-10.3
from 10-Q 16 pages Change in Control Severance Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Ligand Pharmaceuticals Incorporated Director Compensation and Stock Ownership Policy (Amended and Restated Effective April 19, 2023) I. Director Compensation
12/34/56
EX-10.15
from 10-K 11 pages Severance Agreement
12/34/56
EX-10.14
from 10-K 14 pages Separation Agreement
12/34/56
EX-10.9
from 10-K 3 pages Ligand Pharmaceuticals Incorporated Director Compensation and Stock Ownership Policy (Amended and Restated Effective April 13, 2020) I. Director Compensation
12/34/56
EX-10.8
from 10-K 28 pages Ligand Pharmaceuticals Incorporated Amended and Restated Severance Plan and Summary Plan Description Effective Date: November 1, 2022
12/34/56
EX-10.1
from 10-Q 26 pages Amended and Restated Employee Matters Agreement
12/34/56
EX-10.1
from 8-K 31 pages Tax Matters Agreement by and Among Omniab, Inc. (F/K/a Avista Public Acquisition Corp. II) Ligand Pharmaceuticals Incorporated and Omniab Operations, Inc. (F/K/a Omniab, Inc.) Dated as of November 1, 2022 Table of Content I II Tax Matters Agreement
12/34/56
EX-10.5
from 10-Q 7 pages Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement
12/34/56
EX-10.4
from 10-Q 6 pages Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement
12/34/56
EX-10.3
from 10-Q 8 pages Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan Notice of Grant of Stock Option
12/34/56